208 related articles for article (PubMed ID: 9559780)
21. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
Cannon JP; Garey KW; Danziger LH
Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
[TBL] [Abstract][Full Text] [Related]
22. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.
Clemons KV; Stevens DA
J Antimicrob Chemother; 1992 Sep; 30(3):353-63. PubMed ID: 1452501
[TBL] [Abstract][Full Text] [Related]
23. In vitro activities of amphotericin B deoxycholate and liposomal amphotericin B against 604 clinical yeast isolates.
Montagna MT; Lovero G; Coretti C; De Giglio O; Martinelli D; Bedini A; Delia M; Rosato A; Codeluppi M; Caggiano G
J Med Microbiol; 2014 Dec; 63(Pt 12):1638-1643. PubMed ID: 25210203
[TBL] [Abstract][Full Text] [Related]
24. Amphotericin B lipid complex therapy of experimental fungal infections in mice.
Clark JM; Whitney RR; Olsen SJ; George RJ; Swerdel MR; Kunselman L; Bonner DP
Antimicrob Agents Chemother; 1991 Apr; 35(4):615-21. PubMed ID: 2069367
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary extraction and accumulation of lipid formulations of amphotericin B.
Matot I; Pizov R
Crit Care Med; 2000 Jul; 28(7):2528-32. PubMed ID: 10921589
[TBL] [Abstract][Full Text] [Related]
26. Amphotericin B resistance leads to enhanced proteinase and phospholipase activity and reduced germ tube formation in Candida albicans.
Kumar R; Shukla PK
Fungal Biol; 2010; 114(2-3):189-97. PubMed ID: 20943129
[TBL] [Abstract][Full Text] [Related]
27. Renal effects of amphotericin B lipid complex.
Luke RG; Boyle JA
Am J Kidney Dis; 1998 May; 31(5):780-5. PubMed ID: 9590187
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex.
Mitsutake K; Kohno S; Miyazaki Y; Noda T; Miyazaki H; Miyazaki T; Kaku M; Koga H; Hara K
Mycopathologia; 1994 Oct; 128(1):13-7. PubMed ID: 7708087
[TBL] [Abstract][Full Text] [Related]
29. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
30. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole.
Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga MT; Miranda Y; del Valle O; Cossum PA; Wallace TL
J Antimicrob Chemother; 1999 Sep; 44(3):397-401. PubMed ID: 10511410
[TBL] [Abstract][Full Text] [Related]
31. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature.
Martino R
Curr Med Res Opin; 2004 Apr; 20(4):485-504. PubMed ID: 15119986
[TBL] [Abstract][Full Text] [Related]
32. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
33. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
[TBL] [Abstract][Full Text] [Related]
34. Virulence Attributes and Antifungal Susceptibility Profile of Opportunistic Fungi Isolated from Ophthalmic Infections.
Sav H; Ozdemir HG; Altınbas R; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Oct; 181(9-10):653-61. PubMed ID: 27193295
[TBL] [Abstract][Full Text] [Related]
35. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.
Denning DW; Warn P
Antimicrob Agents Chemother; 1999 Nov; 43(11):2592-9. PubMed ID: 10543734
[TBL] [Abstract][Full Text] [Related]
36. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system.
Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP
J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723
[TBL] [Abstract][Full Text] [Related]
37. Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.
Joly V; Bolard J; Saint-Julien L; Carbon C; Yeni P
Antimicrob Agents Chemother; 1992 Feb; 36(2):262-6. PubMed ID: 1605590
[TBL] [Abstract][Full Text] [Related]
38. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model.
Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209
[TBL] [Abstract][Full Text] [Related]
39. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Tiphine M; Letscher-Bru V; Herbrecht R
Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
[TBL] [Abstract][Full Text] [Related]
40. Invitro antifungal susceptibilities of Candida species to liposomal amphotericin B, determined using CLSI broth microdilution, and amphotericin B deoxycholate, measured using the Etest.
Lovero G; Giglio O; Rutigliano S; Diella G; Caggiano G; Montagna MT
J Med Microbiol; 2017 Mar; 66(2):213-216. PubMed ID: 27959780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
